Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques.
about
CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/collagen type XXVExtracellular phosphorylation of the amyloid β-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease.Structures of human Golgi-resident glutaminyl cyclase and its complexes with inhibitors reveal a large loop movement upon inhibitor bindingStructure and physiological function of calpainsCrystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation.Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behaviorImmunotherapy targeting pyroglutamate-3 Aβ: prospects and challengesImmunotherapy for Alzheimer's disease: hoops and hurdlesA window into the heterogeneity of human cerebrospinal fluid Aβ peptidesStructures of Aβ-Related Peptide−Monoclonal Antibody Complexes ,Kinetic and structural characterization of bacterial glutaminyl cyclases from Zymomonas mobilis and Myxococcus xanthusImmunotherapeutic approaches for Alzheimer's diseaseBrain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeuticPurification and Characterization of Recombinant N-Terminally Pyroglutamate-Modified Amyloid-β Variants and Structural Analysis by Solution NMR SpectroscopyMatrix metalloproteinase (MMP) system in brain: identification and characterization of brain-specific MMP highly expressed in cerebellumIdentification of two Sox17 messenger RNA isoforms, with and without the high mobility group box region, and their differential expression in mouse spermatogenesisAmyloid-beta isoform metabolism quantitation by stable isotope-labeled kineticsAn anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 miceGlutaminyl cyclase knock-out mice exhibit slight hypothyroidism but no hypogonadism: implications for enzyme function and drug developmentGlutaminyl cyclases from animals and plants: a case of functionally convergent protein evolution.Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions.Cortical pyroglutamate amyloid-β levels and cognitive decline in Alzheimer's disease.Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study.Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β.Glutaminyl cyclase-mediated toxicity of pyroglutamate-beta amyloid induces striatal neurodegenerationMassive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic modelNeuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease.Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse modelIdentification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosisPyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease.Formation of N-pyroglutamyl peptides from N-Glu and N-Gln precursors in Aplysia neurons.Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease.The Caenorhabditis elegans A beta 1-42 model of Alzheimer disease predominantly expresses A beta 3-42.Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's diseaseThe type of Aβ-related neuronal degeneration differs between amyloid precursor protein (APP23) and amyloid β-peptide (APP48) transgenic miceExperimental verification of a traceback phenomenon in prion infection.Alzheimer's Aβ peptides with disease-associated N-terminal modifications: influence of isomerisation, truncation and mutation on Cu2+ coordination.The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the down critical region.Activity and architecture of pyroglutamate-modified amyloid-β (AβpE3-42) poresDistinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease.
P2860
Q24292980-7DD6A7EB-3BAF-4B0C-8447-A5048E7DD0DAQ24300656-509BD451-CDEA-4C55-ADF2-A51304991443Q24338927-50A6743E-83A8-4CFF-8EB7-5D9CAA323CC2Q24530607-3F6BE006-09F3-4AD9-BA19-4CA55F049038Q24532111-7A724298-F78C-47F9-AC54-7FC34F885721Q24645994-860B0E0D-AA45-4066-A8B4-4CE64C858133Q26745928-6FC9C0E9-8F15-44A6-BF93-84F756006888Q26823877-6E6C5ACE-759F-405E-9311-7C278410DAEDQ27010785-FDC92C47-A008-4236-8CBB-216114B02F72Q27655072-ABAFF302-72BF-4C15-B312-603A34125BB0Q27664659-8A897B4A-B7F0-4CF4-B3D4-9E80F6FABFD4Q28081278-389BCAED-A65E-4A39-9876-EF7A3685BCD6Q28235248-7A017DA1-B462-4C52-A4B5-31D08AA54C36Q28550062-EC812C9E-ED7D-4177-9D04-F211E20993B0Q28566020-6D620710-03D0-48CD-808B-C642C4F3E701Q28592465-C75581FA-FC5F-4DD0-A623-B46A2DFB3310Q28681651-D873441B-A194-43F2-94D6-61A735266FF1Q30316057-449452F6-83A6-466F-ACCF-9819A59E8AAAQ30318462-7E8FABD5-EDB0-46BC-9ABC-04D755B84E91Q30319332-EA48D3D4-B2A6-4EE4-9750-A8DFDA30FD9BQ30320504-F5B82F2E-C05D-4029-BA54-E71AAB8E980AQ30361851-C7B7D5E4-6EDA-4E63-B542-0B581F7F8954Q30422060-57C5B797-43D4-4B13-B1AB-96FD6A23593AQ30423789-B6EB76E9-0243-4272-B0B4-CF7AA8969676Q30446186-37667789-ABBD-462C-9EA3-D2E848B4C495Q30478167-0C21A905-B6A7-41C8-804D-61520F16E991Q30489052-6C7C1909-A106-426F-AA7C-EE3904E41088Q30489966-498ABCC8-FD28-4105-B28B-E0A1FEC460FFQ30497751-66B57FD9-868F-44DE-A608-0A3DE16F7C10Q30512697-A4C2BF51-C671-4B53-884B-D99BBC044EF8Q31916641-A9625542-6319-4F9C-A660-9C153B19ADCBQ31949934-B08A560F-6E6A-45D0-BD9B-E00DCEBA4D13Q33477764-B2667C63-0ED5-4388-A875-3D35690FDAA7Q33624303-EEFE7D0B-82DB-4BD2-B883-027194B6B020Q33715954-17A6B518-1507-4E69-B755-2C83FC2E2229Q33725612-ED516BA4-C766-4BE9-9AF3-C320CAD7DB02Q33786789-C779C0C4-6B54-476D-B308-EC17F78B23ADQ33890879-91BC5D9F-FBD6-438C-A771-43D3B8F976D5Q33894606-35EB86C7-12D5-48CB-AA5F-77DFA0F8817BQ33942884-097BB293-A67B-44AA-90DE-75E619939757
P2860
Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
Dominant and differential depo ...... eta N3(pE), in senile plaques.
@en
Dominant and differential depo ...... eta N3(pE), in senile plaques.
@nl
type
label
Dominant and differential depo ...... eta N3(pE), in senile plaques.
@en
Dominant and differential depo ...... eta N3(pE), in senile plaques.
@nl
prefLabel
Dominant and differential depo ...... eta N3(pE), in senile plaques.
@en
Dominant and differential depo ...... eta N3(pE), in senile plaques.
@nl
P2093
P1433
P1476
Dominant and differential depo ...... eta N3(pE), in senile plaques.
@en
P2093
P304
P356
10.1016/0896-6273(95)90301-1
P407
P577
1995-02-01T00:00:00Z